Modality
Cell Therapy
MOA
Anti-Tau
Target
BTK
Pathway
DDR
PNHPancreatic Ca
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
Nov 2017
→ Jul 2029
Phase 1Current
NCT06664532
349 pts·Pancreatic Ca
2017-11→2029-01·Terminated
NCT03972054
2,320 pts·Pancreatic Ca
2021-06→2029-07·Completed
2,669 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-01-112.8y awayPh2 Data· Pancreatic Ca
2029-07-183.3y awayPh2 Data· Pancreatic Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Termina…
P1/2
Complet…
Catalysts
Ph2 Data
2029-01-11 · 2.8y away
Pancreatic Ca
Ph2 Data
2029-07-18 · 3.3y away
Pancreatic Ca
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06664532 | Phase 1/2 | Pancreatic Ca | Terminated | 349 | UPCR |
| NCT03972054 | Phase 1/2 | Pancreatic Ca | Completed | 2320 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| 369-8021 | Hansoh Pharma | Approved | BTK |